The Miltenberger (Mi) classes represent a group of phenotypes for red cells that carry low frequency antigens associated with the MNSs blood group system. The antigens of this system are known to be located on two sialogly- coproteins denoted as glycophorin A (GP A) and GP B. The structural alterations of seven (classes I, II, III, V, VI, VII, Vili) Mi variants and a related variant (J. L.) have been elucidated. Based on these data and yet incomplete studies of the Mi antigens, the approximate structural alterations in class IV and IX may be predicted. In addition, knowledge of the various structures and partial characterization of the Mi antigens allows one to propose detailed hypotheses concerning the epitopes recognized by the various antibodies that define the Mi subsystem. The understanding of the Mi subsystem at the molecular level paves the way for future studies aimed at a more detailed elucidation of epitopes of Mi-related antibodies, the characterization of novel Mi variants and a search for hypothetical, hitherto unknown Mi-related antibodies.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.